{"id":48969,"date":"2025-11-25T16:55:48","date_gmt":"2025-11-25T08:55:48","guid":{"rendered":"https:\/\/flcube.com\/?p=48969"},"modified":"2025-11-25T16:55:49","modified_gmt":"2025-11-25T08:55:49","slug":"junshis-js001sc-subcutaneous-pd-1-meets-phase-3-endpoint-in-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48969","title":{"rendered":"Junshi&#8217;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC"},"content":{"rendered":"\n<p><strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) announced that its Phase\u202f3 trial <strong>JS001sc-002-III-NSCLC<\/strong> met the primary endpoint, demonstrating that the subcutaneous formulation <strong>JS001sc<\/strong> achieved <strong>non\u2011inferior drug exposure<\/strong> to intravenous <strong>toripalimab (JS001)<\/strong> in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-milestone\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>JS001sc (toripalimab subcutaneous injection)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai Junshi Biosciences (1877.HK; 688180.SH)<\/td><\/tr><tr><td><strong>Trial<\/strong><\/td><td>JS001sc-002-III-NSCLC (NCT06505837)<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Multicenter, open\u2011label, randomized Phase\u202f3<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Toripalimab (JS001) IV + chemotherapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Drug exposure non\u2011inferiority<\/td><\/tr><tr><td><strong>Key Results<\/strong><\/td><td>JS001sc exposure non\u2011inferior to JS001; similar efficacy and safety profiles<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First domestically developed anti\u2011PD\u20111 subcutaneous formulation<\/strong> in Phase\u202f3<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Marketing authorization application (MAA) submission planned<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Anti\u2011PD\u20111 monoclonal antibody (subcutaneous formulation of marketed toripalimab\/LOQTORZI)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Subcutaneous delivery offers <strong>patient convenience<\/strong> and <strong>reduced infusion center burden<\/strong> vs. IV administration<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Only domestic subcutaneous PD\u20111 inhibitor in late\u2011stage development; addresses growing demand for outpatient\u2011friendly oncology therapies<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Expands toripalimab franchise beyond approved IV indications (nasopharyngeal carcinoma, melanoma)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China NSCLC Incidence<\/strong><\/td><td>~800,000 new cases (2024)<\/td><\/tr><tr><td><strong>Recurrent\/Metastatic ns\u2011NSCLC Share<\/strong><\/td><td>~40% of total NSCLC cases<\/td><\/tr><tr><td><strong>PD\u20111\/PD\u2011L1 Market Size<\/strong><\/td><td>\u00a518\u202fbillion (US$2.5\u202fbillion) in China<\/td><\/tr><tr><td><strong>Subcutaneous Penetration<\/strong><\/td><td>&lt;5% of PD\u20111\/PD\u2011L1 market; high growth potential<\/td><\/tr><tr><td><strong>Peak Sales Forecast (JS001sc)<\/strong><\/td><td><strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (US$340\u2011470\u202fmillion) by 2031<\/td><\/tr><tr><td><strong>Competitive Landscape:<\/strong> <strong>Merck\u2019s Keytruda SC<\/strong> approved globally but not yet in China; <strong>JS001sc<\/strong> could be <strong>first\u2011to\u2011market<\/strong> subcutaneous anti\u2011PD\u20111 in China<\/td><td><\/td><\/tr><tr><td><strong>Reimbursement Path:<\/strong> Subcutaneous formulations typically receive favorable NRDL evaluation due to reduced healthcare resource utilization<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding JS001sc\u2019s regulatory submission, market potential, and commercial launch timeline. Actual results may differ materially due to risks including NMPA review outcomes, competitive responses, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48977,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,899,296,18,900],"class_list":["post-48969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-1877","tag-junshi-biosciences","tag-pd-1-l1","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi&#039;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48969\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi&#039;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48969\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T08:55:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T08:55:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi&#8217;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC\",\"datePublished\":\"2025-11-25T08:55:48+00:00\",\"dateModified\":\"2025-11-25T08:55:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504.webp\",\"keywords\":[\"Clinical trial results\",\"HKG: 1877\",\"Junshi Biosciences\",\"PD-1\\\/L1\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48969#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48969\",\"name\":\"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504.webp\",\"datePublished\":\"2025-11-25T08:55:48+00:00\",\"dateModified\":\"2025-11-25T08:55:49+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\\\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48969\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48969#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi&#8217;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48969","og_locale":"en_US","og_type":"article","og_title":"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.","og_url":"https:\/\/flcube.com\/?p=48969","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T08:55:48+00:00","article_modified_time":"2025-11-25T08:55:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48969#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48969"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi&#8217;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC","datePublished":"2025-11-25T08:55:48+00:00","dateModified":"2025-11-25T08:55:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48969"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48969#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","keywords":["Clinical trial results","HKG: 1877","Junshi Biosciences","PD-1\/L1","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48969#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48969","url":"https:\/\/flcube.com\/?p=48969","name":"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48969#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48969#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","datePublished":"2025-11-25T08:55:48+00:00","dateModified":"2025-11-25T08:55:49+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase\u202f3 trial JS001sc-002-III-NSCLC met the primary endpoint, demonstrating that the subcutaneous formulation JS001sc achieved non\u2011inferior drug exposure to intravenous toripalimab (JS001) in first\u2011line recurrent\/metastatic non\u2011squamous NSCLC, with comparable efficacy and safety.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48969#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48969"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48969#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","width":1080,"height":608,"caption":"Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48969#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi&#8217;s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48969"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48969\/revisions"}],"predecessor-version":[{"id":48978,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48969\/revisions\/48978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48977"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}